MARKETS
Technology

Tempus AI Announces Initiative To Build Research Platform Containing 100K Whole Genomes Linked To Longitudinal Clinical Information Over Next Several Years

Sep 11, 2026 · 08:31 AM ET· updated 1h ago

The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million GenomesTempus AI, Inc. (NASDAQ:TEM) today

Share
Why It Matters

Tempus AI is building a huge library of genetic information from 100,000 people to help doctors understand diseases better. This shows the company is investing in a long term plan, which hints at confidence in their business direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.